LONZA GROUP AG

ISIN: CH0013841017 WKN: 1384101 Asset Class: Stock



Company Profile

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	1 2	20	1 2	20	04	
Financial figures		2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity	
Current assets	4,885,000,000		5,712,000,000		5,933,000,000		
Common stock capital		74,000,000		74,000,000		74,000,000	
Fixed assets	12,198,000,000		11,845,000,000		10,758,000,000		
Equity capital of a company		9,512,000,000		10,665,000,000		9,823,000,000	
Cash and cash equivalents	1,468,000,000		1,339,000,000		1,582,000,000		
Accrued liabilities		425,000,000		407,000,000		465,000,000	
Other assets	-		-		-		
Current liabilities		2,763,000,000		3,080,000,000		2,370,000,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		4,808,000,000		3,812,000,000		4,498,000,000	
Different income		-		-		-	
Other liabilities		752,000,000		793,000,000		731,000,000	
Total assets	17,083,000,000	17,083,000,000	17,557,000,000	17,557,000,000	16,691,000,000	16,691,000,000	

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	18,000	17,494	16,218
Equity ratio	56.03%	61.13%	59.29%
Debt-equity ratio	78.47%	63.58%	68.66%

Others

	2023	2022	2021
Tax Expense Rate	16.81%	15.91%	10.53%

LONZA GROUP AG

ISIN:	CH0013841017	WKN:	1384101	Asset Class:	Stock

Income statement

	2023	2022	2021
Turnover	6,717,000,000	6,223,000,000	5,409,000,000
Net income	654,000,000	1,215,000,000	674,000,000
EBIT	894,301,200	1,549,917,200	877,910,800
Operating income before taxes	803,000,000	1,446,000,000	788,000,000
Cash Flow	1,419,000,000	1,039,000,000	1,220,000,000
Net interest income	-70,000,000	-67,000,000	-69,000,000
Research and development expenses	105,000,000	95,000,000	90,000,000
Income taxes	135,000,000	230,000,000	83,000,000
Result from investments in subsidaries, associates and other	-13,000,000	2,000,000	-28,000,000
Revenues per employee	382,272	364,402	341,656

Board of Directors

Angelica Kohlmann	Member of the administrative board	
Marion Helmes	Member of the administrative board	
Olivier Verscheure	Member of the administrative board	
Roger Nitsch	Member of the administrative board	
Barbara Richmond	Member of the administrative board	
Christoph Mäder	Member of the administrative board	
Jürgen B. Steinemann	Member of the administrative board	

Members of Management Board

Chairman of Managing Board
Member of Executive Committee